Save 40% on Braftovi from Europe.
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
Manufacturer for European Braftovi: PIERRE FABRE MEDICAMENT PRODUCTION Site Progipharm, Rue du Lycée 45500 GIEN France
Information about Braftovi (Encorafenib)
Braftovi (Encorafenib) is primarily used in the treatment of adult patients with metastatic melanoma that is positive for the BRAF V600E or V600K mutation. It is often used in combination with another medication called binimetinib, which is a MEK inhibitor, as part of a regimen for treating this type of melanoma. It may also be used in other cancer types with BRAF mutations, depending on the specific clinical guidelines and approval.
Product Highlights:
- Used for the treatment of adult patients with metastatic melanoma with a BRAF V600E or V600K mutation. Often used in combination with binimetinib for enhanced effectiveness.
- Targets and inhibits mutated BRAF proteins, which are involved in the growth and spread of cancer cells in BRAF-mutant cancers.
- Often used in combination with binimetinib, a MEK inhibitor, to target different points in the cancer signaling pathway.
- Encorafenib is the active ingredient in Braftovi. It specifically targets and inhibits the BRAF V600E and V600K mutations, which are involved in the growth of cancer cells.
Key Ingredient:
Key Benefits:
- Encorafenib specifically targets cancer cells with the BRAF V600E or V600K mutation, which can lead to more effective treatment with potentially fewer side effects compared to non-targeted therapies.
- When used in combination with binimetinib, it enhances treatment efficacy by targeting different points in the same cancer signaling pathway.
- Clinical studies have shown that Braftovi, especially in combination with binimetinib, can lead to improved progression-free survival and response rates in patients with BRAF-mutant melanoma.
Direction for Use:
- The standard dose is one tablet taken orally once daily, though the exact dosage and schedule should be determined by a healthcare provider based on individual patient needs and response.
- Tablets should be swallowed whole and not crushed, chewed, or broken. It can be taken with or without food.
- It’s important to take the medication at the same time each day to maintain consistent blood levels of the drug.
Safety Concern:
- Common side effects include fatigue, nausea, diarrhea, skin rash, and liver enzyme abnormalities. Serious side effects may include liver problems, vision changes, or severe skin reactions.
- Regular monitoring of liver function tests and other relevant blood tests is recommended during treatment. Patients should also be monitored for any signs of new or worsening side effects.
Avoid Braftovi (Encorafenib) If:
- If you have a known hypersensitivity or allergy to encorafenib or any of the other components in the medication.
- Use is generally not recommended in patients with severe liver impairment due to increased risk of adverse effects.
- It should be avoided during pregnancy due to potential harm to the fetus. Women of childbearing potential should use effective contraception during treatment.
- Avoid using Braftovi in combination with certain other medications that may interact adversely. Always consult with a healthcare provider about all other medications being taken.
